Search Results - "Nagraj, Praneeta"

Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole by Abbas, Richat, Childress, Ann C., Nagraj, Praneeta, Rolke, Richard, Berry, Sally A., Palumbo, Donna R.

“…Methylphenidate hydrochloride extended-release chewable tablet (MPH ERCT) is approved for treatment of attention deficit hyperactivity disorder in patients…”
Get full text

THU-317 - Real-world experience of Odevixibat in adults with genetic disorders of cholestasis by Trivedi, Palak, Borghi, Alberto, Engelmann, Cornelius, Hegade, Vinod, Hohenester, Simon, Joshi, Deepak, Monkelbaan, Jan F., Morgando, Anna, Nagraj, Praneeta, Valcheva, Velichka

Get full text

Real-world experience of Odevixibat in adults with genetic disorders of cholestasis by Trivedi, Palak, Borghi, Alberto, Engelmann, Cornelius, Hegade, Vinod, Hohenester, Simon, Joshi, Deepak, Monkelbaan, Jan F., Morgando, Anna, Nagraj, Praneeta, Valcheva, Velichka

Get full text

4.7 EFFICACY OF METHYLPHENIDATE EXTENDED-RELEASE CHEWABLE TABLETS IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: OPEN-LABEL, DOSE-OPTIMIZATION PERIOD OUTCOMES by Wigal, Sharon B., PhD, Childress, Ann Catherine, MD, Berry, Sally, MD, PhD, Belden, Heidi, PharmD, Chappell, Phillip B., MD, MBA, Wajsbrot, Dalia, Nagraj, Praneeta, Abbas, Richat, PhD, Palumbo, Donna R., PhD

“…Objectives: To further examine the efficacy and safety of open-label (OL) methylphenidate, extended-release chewable tablets (MPH ERCT; 20-60 mg) in children…”
Get full text